共 50 条
- [1] COMPARISON OF CLINICAL OUTCOME BETWEEN GEFITINIB AND ERLOTINIB TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 OR EXON 21 MUTATIONS[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1204 - S1205Lim, Sung HeeLee, Ji YunKim, MoonjinKim, SungminJung, HyunaeChang, Won JinChoi, Moon KiSun, Jong-MuHong, Jung YongLee, Su JinAhn, Jin SeokPark, KeunchilAhn, Myung-Ju
- [2] Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 839 - 844Riely, GJPao, WPham, DKLi, ARRizvi, NVenkatraman, ESZakowski, MFKris, MGLadanyi, MMiller, VA
- [3] The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (04) : 687 - 694Sun, Jong-MuWon, Young-WoongKim, Seung TaeKim, Jung HoonChoi, Yoon-LaLee, JeeyunPark, Yeon HeeAhn, Jin SeokPark, KeunchilAhn, Myung-Ju
- [4] The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients[J]. Journal of Cancer Research and Clinical Oncology, 2011, 137 : 687 - 694Jong-Mu SunYoung-Woong WonSeung Tae KimJung Hoon KimYoon-La ChoiJeeyun LeeYeon Hee ParkJin Seok AhnKeunchil ParkMyung-Ju Ahn
- [5] Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations[J]. JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (11) : 947 - 952Won, Young-WoongHan, Ji-YounLee, Geon KookPark, Seog-YunLim, Kun YoungYoon, Kyong-AhYun, TakKim, Heung TaeLee, Jin Soo
- [6] Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21[J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 506 - 511Lim, Sung HeeLee, Ji YunSun, Jong-MuAhn, Jin SeokPark, KeunchilAhn, Myung-Ju
- [7] Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3908 - 3914Jackman, David M.Yeap, Beow Y.Sequist, Lecia V.Lindeman, NealHolmes, Alison J.Joshi, Victoria A.Bell, Daphne W.Huberman, Mark S.Halmos, BalazsRabin, Michael S.Haber, Daniel A.Lynch, Thomas J.Meyerson, MatthewJohnson, Bruce E.Jaenne, Pasi A.
- [8] EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR BRAIN METASTASIS IN NON-SMALL CELL LUNG CANCER PATIENTS HARBORING EITHER EXON 19 OR 21 MUTATIONS[J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S657 - S657Kim, Kyu-PyoLee, Dae-HoLee, Jungshin J.Suh, CheolwonKim, Sang-WeLee, Jae CheolChoi, Chang-MinJang, Se JinChoi, Jene
- [9] Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Kim, K.Lee, D. H.Lee, J.Suh, C.Kim, S.Lee, J. C.Choi, C.Jang, S. J.Choi, J.
- [10] Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib[J]. ADVANCES IN THERAPY, 2011, 28 (02) : 126 - 133Heigener, David F.Reck, Martin